Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments

Cell Rep. 2019 Dec 17;29(12):3974-3982.e4. doi: 10.1016/j.celrep.2019.11.071.

Abstract

The essentiality of fatty acid synthesis (FASII) products in the human pathogen Staphylococcus aureus is the underlying rationale for FASII-targeted antimicrobial drug design. Reports of anti-FASII efficacy in animals support this choice. However, restricted test conditions used previously led us to investigate this postulate in a broader, host-relevant context. We report that S. aureus rapidly adapts to FASII antibiotics without FASII mutations when exposed to host environments. FASII antibiotic administration upon signs of infection, rather than just after inoculation as commonly practiced, fails to eliminate S. aureus in a septicemia model. In vitro, serum lowers S. aureus membrane stress, leading to a greater retention of the substrates required for environmental fatty acid (eFA) utilization: eFAs and the acyl carrier protein. In this condition, eFA occupies both phospholipid positions, regardless of anti-FASII selection. Our results identify S. aureus membrane plasticity in host environments as a main limitation for using FASII antibiotics in monotherapeutic treatments.

Keywords: AFN-1252; antibiotic resistance; conditional antibiotic adaptation; fatty acid stress; firmicute pathogens; infection; membrane phospholipids; treatment failure; triclosan.

MeSH terms

  • Adaptation, Physiological*
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Bacterial
  • Fatty Acids / metabolism*
  • Female
  • Host-Pathogen Interactions*
  • Mice
  • Mice, Inbred BALB C
  • Sepsis / drug therapy
  • Sepsis / microbiology
  • Sepsis / pathology*
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / microbiology
  • Staphylococcal Infections / pathology*
  • Staphylococcus aureus / drug effects*

Substances

  • Anti-Bacterial Agents
  • Fatty Acids